Skip to content

DMT: all studies

Page 18 of 160: studies 171 to 180 of 1,593, newest first. Back to the DMT overview

Research

Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics.

Frontiers in Psychiatry November 6, 2024 Cristiano Chaves, Rafael G. Dos Santos, Serdar Dursun et al. 11 citations

The "wine of jurema", used in ancient Brazilian shamanic rituals, is rich in N,N-dimethyltryptamine (DMT), a naturally occurring tryptamine like serotonin and melatonin. Widely found in plants and animals, DMT is the main component of some botanical tisanes used for centuries as a channel of communication with the otherworld (1, 2). Despite being classified as a "classical psychedelic” (2-4),...

DOI: 10.3389/fpsyt.2024.1485337 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health treatment Pharmacology Therapeutic research

Psychedelic Therapy: A Primer for Primary Care Clinicians-N,N-Dimethyltryptamine and Ayahuasca: Erratum.

American Journal of Therapeutics November 1, 2024

The first sentence in the Limitations section of the abstract for “Psychedelic Therapy: A Primer for Primary Care Clinicians - N,N-Dimethyltryptamine and Ayahuasca” stated:“There has only been a single published double-blind randomized controlled trial on ayahuasca and 2 on DMT.” The end of this sentence is incorrect. There are no published, double-blind randomized controlled trials on DMT as...

Inhaled Dimethyltryptamine (DMT): Use Patterns and Predictors of Consumption Frequency.

Journal of Psychoactive Drugs October 15, 2024 Jamie E Parnes, Mitch Earleywine

Despite increasing interest in psychedelics and their potential therapeutic effects, research on inhaled N,N-Dimethyltryptamine (DMT) remains limited. Inhaled DMT has a reputation for rapid, dramatic onset and a brief duration, but correlates of use frequency remain poorly understood. A sample recruited from relevant internet sites, including nearly 400 people who had inhaled DMT, reported...

Complex slow waves radically reorganise human brain dynamics under 5-MeO-DMT

bioRxiv (Cold Spring Harbor Laboratory) October 7, 2024 George Blackburne, Rosalind McAlpine, Marco S. Fabus et al. 8 citations preprint

Abstract 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a psychedelic drug known for its uniquely profound effects on subjective experience, reliably eradicating the perception of time, space, and the self. However, little is known about how this drug alters large-scale brain activity. We collected naturalistic electroencephalography (EEG) data of 29 healthy individuals before and after...

DOI: 10.1101/2024.10.04.616717 (opens in new tab) Full text (opens in new tab) Dynamics music Brain waves Human brain Electroencephalography +1

Continuous flow synthesis of N,N-dimethyltryptamine (DMT) analogues with therapeutic potential.

RSC Medicinal Chemistry October 7, 2024 Andreas Simoens, Andreas Dejaegere, Marthe Vandevelde et al. 2 citations

Herein, we describe the continuous flow synthesis and in-line extraction of N,N-dimethyltryptamine (DMT) and several of its analogues using a Fischer indole reaction, along with a larger gram scale synthesis (4.75 g) of the model compound. These products could then be quickly transformed into their respective fumarate salts, making them easier to handle and stable for long time storage using a...

DOI: 10.1039/d4md00562g (opens in new tab) Full text (opens in new tab) Psychedelics Pharmaceutical manufacturing Mental health treatments Drug synthesis +1

Autonomic nervous system activity correlates with peak experiences induced by DMT and predicts increases in well-being.

Journal of Psychopharmacology October 1, 2024 Valerie Bonnelle, Amanda Feilding, Fernando E. Rosas et al. 16 citations

Non-ordinary states of consciousness induced by psychedelics can be accompanied by so-called "peak experiences," characterized at the emotional level by their intensity and positive valence. These experiences are strong predictors of positive outcomes following psychedelic-assisted therapy, and it is therefore important to better understand their biology. Despite growing evidence that the...

Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat

Journal of Psychopharmacology September 27, 2024 Daniel Meling, Klemens Egger, Jovin Mueller et al. 15 citations

Background: In recent years, both meditation and psychedelics have attracted rapidly increasing scientific interest. While the current state of evidence suggests the promising potential of psychedelics, such as psilocybin, to enhance meditative training, it remains equivocal whether these effects are specifically bound to psilocybin or if other classical psychedelics might show synergistic...

Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors.

Cellular and Molecular Life Sciences September 10, 2024 Klemens Egger, Helena Aicher, Paul Cumming et al. 30 citations

The potent hallucinogen N,N-dimethyltryptamine (DMT) has garnered significant interest in recent years due to its profound effects on consciousness and its therapeutic psychopotential. DMT is an integral (but not exclusive) psychoactive alkaloid in the Amazonian plant-based brew ayahuasca, in which admixture of several β-carboline monoamine oxidase A (MAO-A) inhibitors potentiate the activity...

DMT – psychodelik otwierający duszę

Kosmos August 8, 2024 Izabela Szpręgiel

Dimethyltryptamine (DMT), which is a psychedelic substance, has been a target of neuropharmacological research for years, mainly because of its potential use in the treatment of psychiatric disorders. The pineal gland is the best studied organ for endogenous DMT synthesis. At the same time, the role of DMT has not been clearly established. The association of the pineal gland with endogenous DMT...

Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants.

Journal of Psychopharmacology August 1, 2024 James Jonathan Rucker, Claire T. Roberts, Mathieu Seynaeve et al. 32 citations

To investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BPL-003, a novel intranasal benzoate salt formulation of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), in healthy participants. In all, 44 psychedelic-naïve participants enrolled in the double-blind, placebo-controlled single ascending dose study (1-12 mg BPL-003). Concentrations of 5-MeO-DMT and its...